Phase II study of pre-emptive therapy for low-level positive cytomegalovirus antigenemia by low-dose valganciclovir after allogeneic hematopoietic stem cell transplantatio

Phase 2

Recruiting

• Conditions: Patients with low-level positive cytomegalovirus antigenemia after allogeneic hematopoietic stem cell transplantation

• Registration Number: JPRN-UMIN000004792
• Lead Sponsor: Dept of Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-01-01
• Study Completion: 2011-06-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Negative cytomegalovirus antibodies of both of donors and recipients T-cell depleted or CD34-positive cell selected transplantation Gut GVHD (>=stage 2) HLA more than 2 locus disparity

Study & Design

• Study Type: Interventional
• Study Design: Not specified